Cytyc submits cervical premarket approval (PMA) supplement
This article was originally published in Clinica
Executive Summary
Cytyc hopes to widen the appeal of its cervical cancer screening system by seeking approval for use with the most common smear collection device, the cytobrush/spatula. The ThinPrep screening system, which disperses rinsed cells onto slides for visual assessment, was approved by the US FDA in May but only for samples taken with a broom sampler (see Clinica No 707, p 18).